Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Christopher Carlson
Fred Hutchinson Cancer Research Center, Department: Na
Should you be removed from our database? Contact us at [email protected]. Read more below.
Adpative Biotechnologies Corporation
Other : Intellectual property rights from the awardee institution
See response attached.
Impact of primary tumor development stage on prognosis and outcome in B-ALL
B-cell Acute Lymphocytic Leukemia (B-ALL) is the most common cancer in children; while great progress has been made in the development of treatments for B-ALL, approximately 20% of patients still fail to respond to standard therapies. This study aims to enhance our understanding of the basic biology of an aggressive sub- type of B-ALL, which is hypothesized to derive from an unusually early precursor of B cells. If this hypothesis bears out, the proposed research could plausibly identify effective therapeutic avenues for a subset of B-ALL patients who fail to respond to standard treatment protocols.
Filed on July 15, 2014.
Tell us what you know about Christopher Carlson's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Christopher Carlson filed other conflict of interest disclosures with the NIH:
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Christopher Carlson | Fred Hutchinson Cancer Research Center | Conflict of Interest | Adpative Biotechnologies Corporation | $40,000 - $59,999 |
| Christopher Carlson | Fred Hutchinson Cancer Research Center | Conflict of Interest | Adpative Biotechnologies Corporation | Value cannot be readily determined |
| Christopher Carlson | Fred Hutchinson Cancer Research Center | Conflict of Interest | Adpative Biotechnologies Corporation | Value cannot be readily determined |
| Christopher Carlson | Fred Hutchinson Cancer Research Center | Conflict of Interest | Adpative Biotechnologies Corporation | Value cannot be readily determined |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.